Quantum Genomics SA (PA:ALQGC) reported its yearly results, which highlighted the significant progress the company has made towards the commercialisation of its product, QGC001, for treatment of hypertension (HT) and heart failure (HF). In 2016, the company both completed a 34-person Phase II HT trial (results expected June 2017) and initiated a 75-person European Phase II trial examining the drug for HF (results early 2018). The company is also set up to initiate a US Phase II for HT in H217.
HF at full sail
The company announced that all 10 centres in its Phase II HF trial are now enrolling patients. The trial will examine changes in the HF biomarker N-terminal pro b-type natriuretic peptide over the course of 28 days in diagnosed worsening HF patients. The trial is expected to be completed by the end of 2017 and we expect a data readout shortly afterwards in H118.
To read the entire report Please click on the pdf File Below